Last reviewed 2026-04-20 · How we verify

Bat (bat)

Pfizer's BAT is a marketed drug used to treat various seizure disorders and postherpetic neuralgia. It is a generic medication with multiple manufacturers. BAT's mechanism involves the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. The drug is indicated for patients 12 years of age and older with epilepsy. BAT's clinical differentiation lies in its ability to treat a range of seizure disorders. The commercial significance of BAT is its revenue generation through generic manufacturing. Pipeline developments for BAT are not specified.

At a glance

Approved indications

• Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy
• Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy
• Treatment of primary generalized tonic-clonic seizures in patients 2 years of age and older with epilepsy
• Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older with epilepsy
• Treatment of postherpetic neuralgia in adults
• Treatment of neuropathic pain associated with diabetic peripheral neuropathy in adults
• Treatment of fibromyalgia in adults
• Treatment of chronic pain associated with adult patients with multiple sclerosis
• Treatment of post-traumatic stress disorder (PTSD) in adults
• Treatment of treatment-resistant depression in adults
• Treatment of major depressive disorder in adults
• Treatment of generalized anxiety disorder in adults
• Treatment of insomnia in adults
• Treatment of migraine in adults
• Treatment of epilepsy in patients with a history of status epilepticus
• Treatment of epilepsy in patients with a history of status epilepticus
• Treatment of epilepsy in patients with a history of status epilepticus
• Treatment of epilepsy in patients with a history of status epilepticus
• Treatment of epilepsy in patients with a history of status epilepticus
• Treatment of epilepsy in patients with a history of status epilepticus

Common side effects

• Anemia
• Neutrophil count decreased
• Creatinine increased
• Fatigue
• Peripheral sensory neuropathy
• Platelet count decreased
• Proteinuria
• Hypertension
• Increase in depressive symptoms
• Imminent and active suicidal intent

Drug interactions

• Aspirin
• Warfarin
• Clopidogrel
• Pentoxifylline
• Dipyridamole
• Alteplase
• Reteplase
• Tenecteplase
• Urokinase
• Streptokinase
• Abciximab
• Eptifibatide

Key clinical trials

• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
• The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.